One patient (patient 11) had previously been included in a clinical phase I trial where DCs transfected with mRNA encoding p53, survivin or hTERT were evaluated in patients with metastatic breast cancer or malignant melanoma (Engell-Noerregaard et al. trial ongoing, see Additional file 1 for further information). The gene discussed is TP53; the disease is melanoma.